{"entity":{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","aka":[],"tldr":"A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.","summary":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) is a phase 2 interventional study registered as NCT02768363 by Candel Therapeutics, Inc., with 187 participants enrolled, started 2016-05 and due to reach its primary completion in 2024-11. Interventions recorded: aglatimagene besadenovec, placebo, valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02768363","url":"https://clinicaltrials.gov/study/NCT02768363"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":["candel-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02768363","phase":"2","setting":"A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer","sponsor":"Candel Therapeutics, Inc.","enrolled":187,"outcomes":[]},"route":"/trials/nct02768363/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/"}],"company":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"}]}}